News

BMO downgrades Biogen, asserts company is spending too much on controversial Alzheimer’s drug

Biogen’s new Alzheimer’s drug aduhelm saw limited pickup in its first few months on the market.

What's your reaction?

Excited
0
Happy
0
In Love
0
Not Sure
0
Silly
0

You may also like

Leave a reply

Your email address will not be published. Required fields are marked *

More in:News